| Miss Emma Margaret Movick, AUD | |
|
446 Old Newport Blvd Ste 100, Newport Beach, CA 92663-4246 | |
| (949) 631-4327 | |
| (949) 631-2030 |
| Full Name | Miss Emma Margaret Movick |
|---|---|
| Gender | Female |
| Speciality | Audiologist |
| Location | 446 Old Newport Blvd Ste 100, Newport Beach, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255000410 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | AU3632 (California) | Primary |
| Provider Name | Shohet Ear Associates Medical Group Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1144420738 PECOS PAC ID: 4587610258 Enrollment ID: O20050324001291 |
News Archive
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced that the company will present a comprehensive analysis of its recently completed Phase 2b clinical trial of EVP-6124 in Alzheimer's disease at the Alzheimer's Association International Conference 2012 (AAIC), being held July 14-19, 2012 in Vancouver, British Columbia.
American Medical Systems Holdings, Inc. (NASDAQ: AMMD) (the "Company"), today announced the results of its exchange offer (the "Exchange Offer") in which the Company offered $1,000 principal amount of its newly issued 4.00% Convertible Senior Subordinated Notes due 2041 (the "2041 Notes") in exchange for each $1,000 principal amount of its outstanding 3.25% Convertible Senior Subordinated Notes due 2036 (the "2036 Notes"), for up to $250 million, and no less than $100 million, aggregate principal amount of 2036 Notes.
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved a new indication for MICARDIS® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. MICARDIS® is the first treatment in its class to be approved for this indication.
Heart surgeons don't have to choose between taking a coronary-bypass patient off the popular anti-clotting drug clopidogrel (Plavix) after off-pump heart bypass surgery or having the patient bleed excessively in the days following surgery, according to a new study by researchers at Jefferson Medical College.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Miss Emma Margaret Movick, AUD 446 Old Newport Blvd Ste 100, Newport Beach, CA 92663-4246 Ph: (949) 631-4327 | Miss Emma Margaret Movick, AUD 446 Old Newport Blvd Ste 100, Newport Beach, CA 92663-4246 Ph: (949) 631-4327 |
News Archive
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced that the company will present a comprehensive analysis of its recently completed Phase 2b clinical trial of EVP-6124 in Alzheimer's disease at the Alzheimer's Association International Conference 2012 (AAIC), being held July 14-19, 2012 in Vancouver, British Columbia.
American Medical Systems Holdings, Inc. (NASDAQ: AMMD) (the "Company"), today announced the results of its exchange offer (the "Exchange Offer") in which the Company offered $1,000 principal amount of its newly issued 4.00% Convertible Senior Subordinated Notes due 2041 (the "2041 Notes") in exchange for each $1,000 principal amount of its outstanding 3.25% Convertible Senior Subordinated Notes due 2036 (the "2036 Notes"), for up to $250 million, and no less than $100 million, aggregate principal amount of 2036 Notes.
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved a new indication for MICARDIS® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. MICARDIS® is the first treatment in its class to be approved for this indication.
Heart surgeons don't have to choose between taking a coronary-bypass patient off the popular anti-clotting drug clopidogrel (Plavix) after off-pump heart bypass surgery or having the patient bleed excessively in the days following surgery, according to a new study by researchers at Jefferson Medical College.
› Verified 5 days ago
Adrienne Klyne Waninger, AU.D Audiologist Medicare: Accepting Medicare Assignments Practice Location: 500 Old Newport Blvd Ste 101, Newport Beach, CA 92663 Phone: 949-642-7935 Fax: 949-642-2950 | |
Howard T Mango, Audiologist Medicare: Accepting Medicare Assignments Practice Location: 500 Old Newport Blvd, Ste 101, Newport Beach, CA 92663 Phone: 949-642-7935 Fax: 949-642-2950 | |
Katherine Elizabeth Slezewick, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 500 Old Newport Blvd Ste 101, Newport Beach, CA 92663 Phone: 949-642-7935 Fax: 949-642-2950 | |
Monica Paige Muncy, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 500 Old Newport Blvd Ste 101, Newport Beach, CA 92663 Phone: 949-642-7935 Fax: 949-642-2950 | |
Hannah C Williams, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 500 Old Newport Blvd, Suite 101, Newport Beach, CA 92663 Phone: 949-642-7935 Fax: 949-642-2950 | |
Blake B Wimmer, AUD Audiologist Medicare: Medicare Enrolled Practice Location: 500 Old Newport Blvd Ste 101, Newport Beach, CA 92663 Phone: 949-642-7925 Fax: 949-642-2950 | |
Christine Mai-vy Nguyen, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 500 Old Newport Blvd Ste 101, Newport Beach, CA 92663 Phone: 949-642-7935 Fax: 949-642-2950 |